Patient Survey: Experience with Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplant
If you had an allogeneic transplant (using donor marrow or blood), you can help by completing our survey.
Lymphoma Canada AND MYElomA CANADA ARE preparing a submission for the Canadian Agency for Drugs and Technology in Health (CADTH) Common Drug Review (CDR).
The drug that will soon be reviewed by CDR for patients who have had an allogeneic stem cell transplant is Letermovir – an anti-viral medication that is given after transplant to prevent infection with a virus called CMV.
The survey provides us with the patient input required for the submission. CDR uses this information to help them make recommendations to the provinces and territories regarding funding for new drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Wednesday, December 20th and should only take 10 minutes of your time.
You may access the survey by clicking the link below.
Please share and help us spread the word.
Thank you for your support.